[HTML][HTML] Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists

M Lucey, P Pickford, S Bitsi, J Minnion, J Ungewiss… - Molecular …, 2020 - Elsevier
M Lucey, P Pickford, S Bitsi, J Minnion, J Ungewiss, K Schoeneberg, GA Rutter, SR Bloom…
Molecular Metabolism, 2020Elsevier
Objective The objective of this study was to determine how pharmacokinetically
advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias,
trafficking, anti-hyperglycaemic efficacy, and appetite suppression. Methods In vitro
signalling responses were measured using biochemical and biosensor assays. GLP-1R
trafficking was determined by confocal microscopy and diffusion-enhanced resonance
energy transfer. Pharmacokinetics, glucoregulatory effects, and appetite suppression were …
Objective
The objective of this study was to determine how pharmacokinetically advantageous acylation impacts on glucagon-like peptide-1 receptor (GLP-1R) signal bias, trafficking, anti-hyperglycaemic efficacy, and appetite suppression.
Methods
In vitro signalling responses were measured using biochemical and biosensor assays. GLP-1R trafficking was determined by confocal microscopy and diffusion-enhanced resonance energy transfer. Pharmacokinetics, glucoregulatory effects, and appetite suppression were measured in acute, sub-chronic, and chronic settings in mice.
Results
A C-terminally acylated ligand, [F1,G40,K41.C16 diacid]exendin-4, was identified that showed undetectable β-arrestin recruitment and GLP-1R internalisation. Depending on the cellular system used, this molecule was up to 1000-fold less potent than the comparator [D3,G40,K41.C16 diacid]exendin-4 for cyclic AMP signalling, yet was considerably more effective in vivo, particularly for glucose regulation.
Conclusions
C-terminal acylation of biased GLP-1R agonists increases their degree of signal bias in favour of cAMP production and improves their therapeutic potential.
Elsevier